CMS to Cover NGS Laboratory Tests for Breast, Ovarian Cancer

The Centers for Medicare and Medicaid Services (CMS) announced that it will begin covering FDA approved/cleared diagnostic tests that use next generation sequencing (NGS) to detect inherited ovarian and breast cancer.

“NGS tests provide the most comprehensive genetic analysis of a patient’s cancer because they enable simultaneous detection of multiple types of genetic alterations,” said CMS Administrator Seema Verma.

The NGS diagnostics provide clinical information that can help physicians develop a personalized cancer treatment plan for each patient.